Nexthera Capital’s Rein Therapeutics RNTX Stock Holding History

Nexthera Capital’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,705	Closed	-$1.27M	–	46
2017 Q2	$1.27M	Buy	+5,705	New	+$1.25M	0.55%	33

Other funds holding RNTX

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Nexthera Capital's RNTX Position: Q3 2017 in Review

Nexthera Capital sold out of Rein Therapeutics (RNTX) in Q3 2017, closing a stake of 5,705 shares — an estimated $1.27M sold.

Nexthera Capital first reported a position in RNTX in Q2 2017 and held it in 1 quarter. The position peaked at $1.27M in Q2 2017. 31 funds tracked by Wall St. Rank hold RNTX as of Q3 2017.

Nexthera Capital reported no remaining Rein Therapeutics position as of Q3 2017 after selling out during the quarter.
Nexthera Capital sold 5,705 Rein Therapeutics shares in Q3 2017, an estimated $1.27M.
Nexthera Capital first reported a position in Rein Therapeutics in Q2 2017 and held it in 1 quarter.
Nexthera Capital's Rein Therapeutics position peaked at $1.27M in Q2 2017.
31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2017.

Based on Nexthera Capital's 13F filing for Q3 2017, filed 14 Nov 2017.